IgA Vasculitis following AstraZeneca/Oxford COVID-19, case report

Nasser  Alzoabi; Jamal Alqahtani; Bader Algamdi; Nada Alghamdi; Ayesha Ahmad; Gaeda  Alkaltham; Tala Beidas; Omar  Alakloby

doi:10.23750/abm.v94i6.12959

IgA Vasculitis following AstraZeneca/Oxford COVID-19, case report

Authors

Nasser Alzoabi
Jamal Alqahtani
Bader Algamdi
Nada Alghamdi a:1:{s:5:"en_US";s:39:"Imam Abdulrahman Bin Faisal University ";}
Ayesha Ahmad
Gaeda Alkaltham
Tala Beidas
Omar Alakloby

DOI: https://doi.org/10.23750/abm.v94i6.12959

Keywords:

IgA vasculitis, AstraZeneca/Oxford COVID-19 vaccine, skin biopsy.

Abstract

Immunoglobulin A (IgA) vasculitis, also known as Henoch–Schönlein purpura, is an immune-mediated vasculitis that affects small vessels. IgA vasculitis could be triggered by numerous conditions including infectious and non-infectious conditions. So far, few reported cases of Covid-19 vaccines related vasculitis. We report a case of IgA vasculitis after AstraZeneca/Oxford COVID-19 vaccine. A 29-year-old healthy man who developed purpuric skin lesions one week after his second AstraZeneca/Oxford COVID-19 vaccine which complicated by glomerulonephritis and gastrointestinal involvement. Skin biopsy revealed fibrinoid necrosis and leukocytoclasia consistent with small vessel vasculitis. Due to the temporal association, AstraZeneca/Oxford COVID-19 vaccine-related IgA vasculitis would be the most likely explanation.

References

World Health Organization (WHO). 2022. Coronavirus COVID-19 Dashboard. [online] Available at: < https://covid19.who.int/>

Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27): 2603-15. doi: 10.1056/NEJMoa2034577.

Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2020; 384(5): 403-16. doi: 10.1056/NEJMoa2035389.

Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vac-cines in the US-December 14, 2020-January 18, 2021. JAMA 2021; 325(11): 1101-02. doi: 10.1001/jama.2021.1967.

CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including an-aphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep 2021; 70(4):125-9.

Verger AA, Pillebout E, Guillevin L, Thervet E, Terrier B. IgA vasculitis (Henoch–Shönlein pur-pura) in adults: Diagnostic and therapeutic aspects. Autoimmun Rev. 2015;14(7):579-85. doi: 10.1016/j.autrev.2015.02.003.

Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis. 2021;78(4):611-613. doi: 10.1053/j.ajkd.2021.06.016.

Bostan E, Zaid F, Akdogan N, Gokoz O. Possible case of mRNA COVID‐19 vaccine‐induced small‐vessel vasculitis. J Cosmet Dermatol. 2022 Jan;21(1):51-53. doi: 10.1111/jocd.14568.

Mücke V, Knop V, Mücke M, Ochsendorf F, Zeuzem S. First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report. BMC Infect Dis. 2021;16;21(1):958. doi: 10.1186/s12879-021-06655-x.

Shahrigharahkoshan S, Gagnon L, Mathieu S. Cutaneous Leukocytoclastic Vasculitis Induction Following ChAdOx1 nCoV-19 Vaccine. Cureus 2021; 13(10): e19005. doi: 10.7759/cureus.19005.

Liang I, Swaminatha S, Lee A. Emergence of de novo cutaneous vasculitis post coronavirus dis-ease (COVID-19) vaccination. Clin Rheumatol. 2022;41(5):1611-1612. doi: 10.1007/s10067-021-05948-5.

Sugita K, Kaneko S, Hisada R. et al. Development of IgA vasculitis with severe glomerulonephri-tis after COVID-19 vaccination: a case report and literature review. CEN Case Rep 2022; 1-6. doi: 10.1007/s13730-022-00695-1.

Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum 1990; 33(8): 1114-21. doi: 10.1002/art.1780330809.